Biogen intends to market nusinersen under the brand name SPINRAZA TM. This name has been conditionally accepted by the FDA and the CHMP and will be confirmed upon approval.

Image source: Biogen, Inc. Biogen, Inc. (BIIB 0.86%) and partner Ionis Pharmaceuticals, Inc. (IONS 4.17%) reported this week that an interim look at a study evaluating the companies' nusinersen as ...

Biogen Inc. announced that the FDA has accepted and the EMA has validated its supplemental New Drug Application for a higher dose regimen of nusinersen, intended for treating spinal muscular ...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Biogen (NASDAQ: BIIB) presented new data demonstrating that earlier initiation of treatment with SPINRAZA ® (nusinersen) may improve motor function outcomes in ...

New Data for Nusinersen Underscore Biogen’s Commitment to Advancing Clinical Research to Improve Outcomes in SMA Provided by GlobeNewswire Jun 27, 2025, 2:00:23 PM.

Biogen has paid Ionis a $75 million license fee after exercising its option to develop and commercialize nusinersen globally. Biogen is now responsible for all nusinersen development, regulatory ...

Biogen has paid $75m to take control of Ionis’ nusinersen for spinal muscular atrophy (SMA) after the drug met its objectives in a phase III trial. The big biotech has said it will now press ahead ...

Biogen and Ionis Pharmaceuticals said their nusinersen treatment for infantile-onset spinal muscular atrophy demonstrated significant improvement in certain motor functions.

* Infants receiving Nusinersen experienced a statistically significant improvement in achievement of motor milestones versus those who didn't * Biogen is now responsible for all Nusinersen ...

SPINRAZA is the standard of care for treating infants, children and adults with spinal muscular atrophy, a rare, genetic neuromuscular disease SPINRAZA was approved under the China National ...

Biogen Inc. BIIB and Ionis Pharmaceuticals IONS revealed that nusinersen, their investigational treatment for spinal muscular atrophy (SMA), met the primary endpoint at interim analysis of the ...

Oct 28 (Reuters) - Biogen Inc : Oct 28 (Reuters) - Biogen Inc : Skip to main content. Exclusive news, data and analytics for financial market professionals Learn more about Refinitiv.